Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$31.96
-4.2%
$39.85
$11.20
$72.98
$7.10B1.3714.03 million shs15.19 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$822.14
-0.6%
$841.16
$711.40
$972.53
$783.91B0.343.15 million shs2.13 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-9.89%-1.36%-34.99%+17.21%+111.22%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.99%-1.25%-6.24%+4.12%+6.66%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
3.2635 of 5 stars
3.12.00.00.02.83.31.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8257 of 5 stars
2.45.03.34.03.42.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.27
Hold$37.3116.75% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7222.82% Upside

Current Analyst Ratings Breakdown

Latest LLY and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$21.00 ➝ $22.00
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/6/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform$21.00 ➝ $21.00
3/6/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell ➝ Sell$27.00 ➝ $27.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
2/26/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$24.00 ➝ $39.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$24.00 ➝ $40.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $35.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$25.00 ➝ $27.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$31.00 ➝ $61.00
2/20/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$18.00 ➝ $21.00
(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$1.48B4.81N/AN/A$1.61 per share19.85
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.31$13.40 per share61.34$15.05 per share54.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$23.55M$0.5472.6361.45N/A8.19%10.97%8.29%5/5/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7170.2126.421.4023.51%85.24%16.19%5/1/2025 (Estimated)

Latest LLY and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/24/2025Q4 2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.09$0.11+$0.02$0.11$494.56 million$481.14 million
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%+15.21%51.24%11 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/A
2.14
1.82
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97

Institutional Ownership

CompanyInstitutional Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
17.71%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
650222.17 million179.79 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable

Recent News About These Companies

Eli Lilly comms head Kathryn Beiser resigns
Eli Lilly and Company stock logo
Medical Stocks To Add to Your Watchlist - March 27th
Lilly adds Alzheimer's to online offerings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$31.96 -1.40 (-4.21%)
Closing price 03:59 PM Eastern
Extended Trading
$32.05 +0.09 (+0.29%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$822.14 -4.62 (-0.56%)
Closing price 03:59 PM Eastern
Extended Trading
$820.80 -1.33 (-0.16%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.